IOB - Delayed Quote USD

0JBU.IL,0P0001H3SO,2434 (0JBU.IL)

26.35

+1.44

+(5.78%)

As of July 23 at 9:00:00 PM GMT+1. Market Open.

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financial results and operational highlights in a conference call on May 8, 2025, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All par

GlobeNewswire 21 hours ago

NTLA
Trump’s FDA Sends a Bullish Signal to Biotech

A vow by the agency’s new commissioner, Marty Makary, to support innovation might ease fears stoked by Health and Human Services Secretary Robert F. Kennedy Jr.

The Wall Street Journal 9 days ago

MFG

MZHOF

RGNX
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Shares of gene therapy companies — including Sarepta Therapeutics — got a lift Monday after FDA's Marty Makary laid out his plans.

Investor's Business Daily 10 days ago

DYN

RNA

SRPT
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on April 1, 2025, it awarded an inducement grant to three new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grant consisted of time-based restricted stock units (“RSUs”) for 8,400 shares of Intellia’s common stock,

GlobeNewswire 28 days ago

NTLA
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient has been dosed in MAGNITUDE-2, a global, pivotal Phase 3 trial of nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). “We are pleased to have dosed the first patient with a treatment that has such stro

GlobeNewswire 28 days ago

NTLA
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks 30 days ago

GLPG

GLPGF

PTCT
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z, also known as NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM). “This is a meani

GlobeNewswire last month

NTLA
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

A week ago, Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) came out with a strong set of yearly numbers that could...

Simply Wall St. last month

NTLA
Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations

Intellia Therapeutics ( NASDAQ:NTLA ) Full Year 2024 Results Key Financial Results Revenue: US$57.9m (up 60% from FY...

Simply Wall St. 2 months ago

NTLA
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics License Application in the second half of 2026 to support plans for U.S. launch in 2027Enrollment in the pivotal Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in patients with transthyretin amyloidosis (ATTR) with cardiomyopathy continues to track ahead of projections; more than 550 total

GlobeNewswire 2 months ago

NTLA
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its fourth quarter and full-year 2024 financial results and operational highlights in a conference call on February 27, 2025, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes be

GlobeNewswire 2 months ago

NTLA
Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is a wholly owned investigational in vivo CRISPR-based therapy in development as a single-dose treatment for this potentially life-threatening d

GlobeNewswire 3 months ago

NTLA
Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital

BMO Capital lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $70 and keeps an Outperform rating on the shares. The company’s AATD discontinuation is the right decision and alleviates Intellia’s financing overhang, but the firm expects investors to question the timing of that decision with Phase 1 trial having just started, the analyst tells investors in a research note. The firm also continues to see Intellia shares as undervalued but warns that this week’s news may pr

TipRanks 3 months ago

NTLA
Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo

Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $60 from $70 and keeps an Overweight rating on the shares. The discontinuation of the Alpha-1 Antitrypsin Deficiency program “makes sense” given the changing landscape, the analyst tells investors. Wells continues to think ATTR amyloidosis with cardiomyopathy is the main value driver and sees quick enrollment in the Phase 3 trial as a promising sign of patient acceptance of gene editing. Published first on TheFly – th

TipRanks 3 months ago

NTLA
Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

Priority programs – NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis – set foundation for significant, near-term value creation Phase 3 HAELO study evaluating NTLA-2002 for HAE to complete enrollment in the second half of 2025; Company plans to submit a Biologics License Application in the second half of 2026More than 550 patients expected to be enrolled by year end within the ongoing MAGNITUDE study for nex-z in ATTR-CM – the progra

GlobeNewswire 3 months ago

NTLA
Here's Why We're Watching Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 4 months ago

NTLA
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.

Investor's Business Daily 5 months ago

NTLA

BBIO

PFE
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

CAMBRIDGE, Mass, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z, also known as NTLA-2001) for the treatment of hereditary transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN). Nex-z

GlobeNewswire 5 months ago

NTLA
Intellia Therapeutics Announces Promising CRISPR Therapy Results

Intellia Therapeutics ( (NTLA) ) just unveiled an announcement. Intellia Therapeutics has unveiled promising Phase 1 clinical trial results for Nexiguran Ziclumeran, a CRISPR-based gene-editing therapy aimed at treating transthyretin amyloidosis. The therapy demonstrated significant reduction in serum TTR levels and showed stabilization or improvement in disease markers over 12 months. The trial highlights Nexiguran’s potential as a one-time treatment option, with favorable safety and tolerabili

TipRanks 5 months ago

NTLA
Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo

Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $70 from $80 and keeps an Overweight rating on the shares. The firm notes that Phase 1 ATTR-CM data for nex-z compare well vs. historical data shown by silencers and stabilizers, despite having a greater proportion of patients with more severe disease. Wells thinks this should bode well for Phase 3 success. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

TipRanks 5 months ago

NTLA

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

0JBU.IL,0P0001H3SO,2434 (0JBU.IL)

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Trump’s FDA Sends a Bullish Signal to Biotech

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Biotech stocks slide as Marks resignation seen being negative for sector

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital

Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

Here's Why We're Watching Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics Announces Promising CRISPR Therapy Results

Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo